378 related articles for article (PubMed ID: 27126805)
1. DNA Damage in Major Psychiatric Diseases.
Raza MU; Tufan T; Wang Y; Hill C; Zhu MY
Neurotox Res; 2016 Aug; 30(2):251-67. PubMed ID: 27126805
[TBL] [Abstract][Full Text] [Related]
2. Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention.
Rossetti AC; Paladini MS; Riva MA; Molteni R
Pharmacol Ther; 2020 Jun; 210():107520. PubMed ID: 32165136
[TBL] [Abstract][Full Text] [Related]
3. Connectivity between mitochondrial functions and psychiatric disorders.
Hroudová J; Fišar Z
Psychiatry Clin Neurosci; 2011 Mar; 65(2):130-41. PubMed ID: 21414088
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine protects against stress-induced oxidative DNA damage in hippocampus during antidepressant testing in mice.
Abdel-Wahab BA; Salama RH
Pharmacol Biochem Behav; 2011 Nov; 100(1):59-65. PubMed ID: 21835191
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and therapeutic implications in psychiatric disorders.
Zhang XY; Yao JK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():197-9. PubMed ID: 23523744
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism.
Smaga I; Niedzielska E; Gawlik M; Moniczewski A; Krzek J; Przegaliński E; Pera J; Filip M
Pharmacol Rep; 2015 Jun; 67(3):569-80. PubMed ID: 25933971
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant Action on Mitochondrial Dysfunction in Psychiatric Disorders.
Adzic M; Brkic Z; Bulajic S; Mitic M; Radojcic MB
Drug Dev Res; 2016 Nov; 77(7):400-406. PubMed ID: 27539538
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial dysfunction and psychiatric disorders.
Rezin GT; Amboni G; Zugno AI; Quevedo J; Streck EL
Neurochem Res; 2009 Jun; 34(6):1021-9. PubMed ID: 18979198
[TBL] [Abstract][Full Text] [Related]
9. Combining redox-proteomics and epigenomics to explain the involvement of oxidative stress in psychiatric disorders.
Andreazza AC
Mol Biosyst; 2012 Oct; 8(10):2503-12. PubMed ID: 22710408
[TBL] [Abstract][Full Text] [Related]
10. [Role of oxidative stress in the pathophysiology of neuropsychiatric disorders].
Nunomura A; Tamaoki T; Motohashi N
Seishin Shinkeigaku Zasshi; 2014; 116(10):842-58. PubMed ID: 25672211
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress markers in affective disorders.
Siwek M; Sowa-Kućma M; Dudek D; Styczeń K; Szewczyk B; Kotarska K; Misztakk P; Pilc A; Wolak M; Nowak G
Pharmacol Rep; 2013; 65(6):1558-71. PubMed ID: 24553004
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in major depressive and anxiety disorders, and the association with antidepressant use; results from a large adult cohort.
Black CN; Bot M; Scheffer PG; Penninx BW
Psychol Med; 2017 Apr; 47(5):936-948. PubMed ID: 27928978
[TBL] [Abstract][Full Text] [Related]
13. Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity.
Assies J; Mocking RJ; Lok A; Ruhé HG; Pouwer F; Schene AH
Acta Psychiatr Scand; 2014 Sep; 130(3):163-80. PubMed ID: 24649967
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications.
Ng F; Berk M; Dean O; Bush AI
Int J Neuropsychopharmacol; 2008 Sep; 11(6):851-76. PubMed ID: 18205981
[TBL] [Abstract][Full Text] [Related]
15. Platelet haemostatic function in psychiatric disorders: Effects of antidepressants and antipsychotic drugs.
Dietrich-Muszalska A; Wachowicz B
World J Biol Psychiatry; 2017 Dec; 18(8):564-574. PubMed ID: 27112326
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric aspects of phosphodiesterases: An overview.
Murthy VS; Mangot AG
Indian J Pharmacol; 2015; 47(6):594-9. PubMed ID: 26729948
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 facilitates recovery from DNA damage after oxidative stress.
Deng G; Su JH; Ivins KJ; Van Houten B; Cotman CW
Exp Neurol; 1999 Sep; 159(1):309-18. PubMed ID: 10486199
[TBL] [Abstract][Full Text] [Related]
18. Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment.
de Bartolomeis A; Avvisati L; Iasevoli F; Tomasetti C
Eur J Pharmacol; 2013 Oct; 718(1-3):502-23. PubMed ID: 23834777
[TBL] [Abstract][Full Text] [Related]
19. L-Acetylcarnitine as a histone acetylation modulator in psychiatric disorders.
Peedicayil J
Psychopharmacology (Berl); 2018 Nov; 235(11):3361-3362. PubMed ID: 30251161
[No Abstract] [Full Text] [Related]
20. Neurosteroids and neuroactive drugs in mental disorders.
Pisu MG; Serra M
Life Sci; 2004 May; 74(26):3181-97. PubMed ID: 15094320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
